Nifty
Sensex
:
:
15746.50
52574.46
63.15 (0.40%)
230.01 (0.44%)

Pharmaceuticals & Drugs - Global

Rating :
54/99

BSE: 500087 | NSE: CIPLA

960.15
21-Jun-2021
  • Open
  • High
  • Low
  • Previous Close
  •  958.00
  •  962.70
  •  950.50
  •  960.90
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1625660
  •  15573.70
  •  982.30
  •  621.05

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 77,433.29
  • 32.21
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 79,245.81
  • 0.52%
  • 4.23

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 36.73%
  • 5.12%
  • 16.25%
  • FII
  • DII
  • Others
  • 23.26%
  • 16.71%
  • 1.93%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.48
  • 4.73
  • 4.17

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.54
  • 4.61
  • 4.83

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.12
  • 3.04
  • 4.09

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 33.25
  • 34.52
  • 31.61

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.58
  • 3.33
  • 3.17

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.85
  • 16.36
  • 14.56

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Net Sales
4,606.45
4,376.19
5.26%
5,168.69
4,371.00
18.25%
5,038.29
4,395.78
14.62%
4,346.16
3,989.02
8.95%
Expenses
3,810.21
3,742.67
1.80%
3,937.81
3,612.67
9.00%
3,861.72
3,486.28
10.77%
3,297.42
3,084.38
6.91%
EBITDA
796.24
633.52
25.69%
1,230.88
758.33
62.31%
1,176.57
909.50
29.36%
1,048.74
904.64
15.93%
EBIDTM
17.29%
14.48%
23.81%
17.35%
23.35%
20.69%
24.13%
22.68%
Other Income
60.13
93.18
-35.47%
86.94
72.13
20.53%
53.47
100.52
-46.81%
65.45
78.37
-16.49%
Interest
27.45
53.00
-48.21%
47.92
46.17
3.79%
39.33
46.07
-14.63%
46.00
52.12
-11.74%
Depreciation
285.19
345.80
-17.53%
248.43
277.89
-10.60%
265.06
282.96
-6.33%
268.98
268.00
0.37%
PBT
543.73
327.90
65.82%
1,021.47
506.40
101.71%
925.65
680.99
35.93%
799.21
662.89
20.56%
Tax
128.22
85.59
49.81%
268.96
152.82
76.00%
263.80
200.55
31.54%
227.78
192.24
18.49%
PAT
415.51
242.31
71.48%
752.51
353.58
112.83%
661.85
480.44
37.76%
571.43
470.65
21.41%
PATM
9.02%
5.54%
14.56%
8.09%
13.14%
10.93%
13.15%
11.80%
EPS
5.13
3.05
68.20%
9.28
4.35
113.33%
8.25
5.85
41.03%
7.17
5.93
20.91%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
19,159.59
17,131.99
16,362.41
15,155.71
14,394.29
13,594.89
11,345.44
10,173.39
8,279.33
7,020.71
6,323.84
Net Sales Growth
11.84%
4.70%
7.96%
5.29%
5.88%
19.83%
11.52%
22.88%
17.93%
11.02%
 
Cost Of Goods Sold
7,351.89
5,991.42
5,784.49
5,438.42
5,317.12
5,089.86
4,270.63
3,874.83
2,952.61
2,739.30
2,775.18
Gross Profit
11,807.70
11,140.57
10,577.92
9,717.29
9,077.17
8,505.03
7,074.81
6,298.56
5,326.72
4,281.41
3,548.66
GP Margin
61.63%
65.03%
64.65%
64.12%
63.06%
62.56%
62.36%
61.91%
64.34%
60.98%
56.12%
Total Expenditure
14,907.16
14,025.88
13,494.26
12,702.32
11,918.50
11,115.22
9,183.74
8,040.34
6,081.48
5,361.86
4,954.60
Power & Fuel Cost
-
327.43
335.11
298.82
251.73
245.92
228.28
218.63
233.12
235.35
198.55
% Of Sales
-
1.91%
2.05%
1.97%
1.75%
1.81%
2.01%
2.15%
2.82%
3.35%
3.14%
Employee Cost
-
3,027.01
2,856.53
2,690.10
2,633.82
2,434.01
1,967.72
1,542.96
1,036.02
772.50
565.59
% Of Sales
-
17.67%
17.46%
17.75%
18.30%
17.90%
17.34%
15.17%
12.51%
11.00%
8.94%
Manufacturing Exp.
-
1,372.03
1,284.94
1,220.67
1,192.77
1,023.49
737.11
644.42
541.58
583.18
627.94
% Of Sales
-
8.01%
7.85%
8.05%
8.29%
7.53%
6.50%
6.33%
6.54%
8.31%
9.93%
General & Admin Exp.
-
1,289.13
1,096.50
1,002.43
868.31
845.89
743.46
638.08
496.81
369.85
288.71
% Of Sales
-
7.52%
6.70%
6.61%
6.03%
6.22%
6.55%
6.27%
6.00%
5.27%
4.57%
Selling & Distn. Exp.
-
1,252.04
1,281.29
1,082.90
1,009.21
818.76
738.87
680.32
466.22
467.61
386.67
% Of Sales
-
7.31%
7.83%
7.15%
7.01%
6.02%
6.51%
6.69%
5.63%
6.66%
6.11%
Miscellaneous Exp.
-
766.82
855.40
968.98
645.54
657.29
497.67
441.10
355.12
194.07
386.67
% Of Sales
-
4.48%
5.23%
6.39%
4.48%
4.83%
4.39%
4.34%
4.29%
2.76%
1.77%
EBITDA
4,252.43
3,106.11
2,868.15
2,453.39
2,475.79
2,479.67
2,161.70
2,133.05
2,197.85
1,658.85
1,369.24
EBITDA Margin
22.19%
18.13%
17.53%
16.19%
17.20%
18.24%
19.05%
20.97%
26.55%
23.63%
21.65%
Other Income
265.99
369.38
476.57
357.65
228.69
208.21
165.55
265.37
222.14
139.52
91.68
Interest
160.70
197.36
168.43
114.23
159.38
206.63
168.29
145.74
33.91
38.34
25.10
Depreciation
1,067.66
1,099.95
1,097.15
949.83
1,322.93
754.22
504.71
372.64
330.48
312.22
273.33
PBT
3,290.06
2,178.18
2,079.14
1,746.98
1,222.17
1,727.03
1,654.25
1,880.04
2,055.60
1,447.81
1,162.49
Tax
888.76
631.20
569.53
250.11
179.76
331.59
400.03
463.38
544.31
306.51
195.22
Tax Rate
27.01%
28.98%
27.39%
14.98%
14.71%
19.20%
24.18%
24.65%
25.98%
21.17%
16.79%
PAT
2,401.30
1,593.98
1,544.87
1,413.31
1,013.38
1,372.01
1,206.07
1,400.73
1,551.06
1,141.30
967.27
PAT before Minority Interest
2,417.66
1,546.98
1,509.61
1,419.35
1,042.41
1,395.44
1,254.22
1,416.66
1,551.06
1,141.30
967.27
Minority Interest
16.36
47.00
35.26
-6.04
-29.03
-23.43
-48.15
-15.93
0.00
0.00
0.00
PAT Margin
12.53%
9.30%
9.44%
9.33%
7.04%
10.09%
10.63%
13.77%
18.73%
16.26%
15.30%
PAT Growth
55.23%
3.18%
9.31%
39.46%
-26.14%
13.76%
-13.90%
-9.69%
35.90%
17.99%
 
EPS
29.83
19.80
19.19
17.55
12.59
17.04
14.98
17.40
19.27
14.18
12.01

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
15,763.00
15,012.28
14,229.19
12,543.66
11,516.22
10,801.49
10,050.35
9,018.68
7,638.93
6,666.13
Share Capital
161.25
161.14
161.02
160.90
160.68
160.59
160.58
160.58
160.58
160.58
Total Reserves
15,548.70
14,794.10
14,001.91
12,320.74
11,266.12
10,557.74
9,868.12
8,858.10
7,478.35
6,505.55
Non-Current Liabilities
2,972.37
4,646.15
4,259.05
4,514.99
1,407.13
2,417.66
2,028.05
1,024.96
824.27
697.34
Secured Loans
304.74
47.70
0.00
0.00
207.00
287.09
317.44
0.00
0.00
15.00
Unsecured Loans
2,064.54
3,782.37
3,662.11
3,645.36
14.88
22.19
0.43
0.55
3.25
2.92
Long Term Provisions
133.27
121.41
137.92
140.52
144.68
1,783.17
1,368.64
713.87
557.78
466.30
Current Liabilities
4,393.14
3,771.51
3,832.22
3,388.91
7,776.05
3,881.13
2,563.58
2,277.63
1,413.19
1,698.54
Trade Payables
2,281.81
1,947.99
2,119.12
1,586.30
1,475.82
1,452.06
979.53
828.36
691.77
720.88
Other Current Liabilities
706.65
541.86
647.04
908.95
1,006.14
654.55
408.67
250.89
489.93
235.28
Short Term Borrowings
447.15
486.16
435.87
467.23
4,969.67
1,392.48
910.47
966.38
10.20
523.06
Short Term Provisions
957.53
795.50
630.19
426.43
324.42
382.04
264.91
232.00
221.29
219.32
Total Liabilities
23,422.79
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01
Net Block
9,558.59
9,546.51
9,949.14
9,508.16
9,368.32
6,829.64
6,496.47
3,609.97
3,215.49
3,094.18
Gross Block
15,009.61
13,790.31
12,960.01
11,370.70
10,167.62
9,561.55
8,676.27
5,317.52
4,626.35
4,240.55
Accumulated Depreciation
5,405.29
4,233.78
3,010.87
1,609.71
799.30
2,731.91
2,179.80
1,707.55
1,410.86
1,146.37
Non Current Assets
11,716.61
11,335.28
11,858.80
12,082.23
12,208.26
9,689.47
9,039.59
5,537.29
4,819.58
4,618.88
Capital Work in Progress
824.53
676.18
981.33
1,682.98
2,060.87
580.90
441.84
377.79
371.17
285.34
Non Current Investment
578.80
490.20
157.66
137.36
176.35
249.76
397.14
415.69
328.59
367.18
Long Term Loans & Adv.
677.08
455.57
514.96
543.67
426.18
1,860.29
1,545.25
971.75
857.53
841.20
Other Non Current Assets
77.61
166.82
255.71
210.06
176.54
168.88
158.89
162.09
46.80
30.98
Current Assets
11,706.18
12,426.63
10,814.10
8,803.56
8,841.23
7,591.29
5,651.97
6,783.98
5,056.81
4,443.13
Current Investments
1,016.52
2,125.79
1,102.21
837.39
582.34
390.02
311.43
2,116.75
940.52
223.59
Inventories
4,377.60
3,964.83
4,044.70
3,519.72
3,808.05
3,780.62
2,895.26
2,387.07
1,850.08
1,906.16
Sundry Debtors
3,891.31
4,150.72
3,102.45
2,582.17
2,356.27
1,997.72
1,638.89
1,668.84
1,553.58
1,490.82
Cash & Bank
1,003.91
618.81
965.61
638.27
871.40
564.26
175.76
143.01
90.46
95.97
Other Current Assets
1,416.84
415.53
480.20
418.17
1,223.17
858.67
630.63
468.31
622.17
726.59
Short Term Loans & Adv.
974.82
1,150.95
1,118.93
807.84
780.03
713.07
595.13
463.21
459.94
533.77
Net Current Assets
7,313.04
8,655.12
6,981.88
5,414.65
1,065.18
3,710.16
3,088.39
4,506.35
3,643.62
2,744.59
Total Assets
23,422.79
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
3,068.45
1,691.14
1,462.76
2,381.76
1,740.81
1,173.43
1,563.31
1,397.67
1,712.76
1,025.10
PBT
2,178.18
2,079.14
1,669.46
1,222.17
1,727.03
1,654.25
1,880.04
2,095.38
1,447.81
1,162.49
Adjustment
1,365.53
1,268.77
1,293.82
1,374.42
950.85
630.05
552.80
283.82
396.66
288.84
Changes in Working Capital
372.99
-1,063.54
-778.48
235.44
-429.38
-718.61
-561.26
-519.84
199.76
-162.03
Cash after chg. in Working capital
3,916.70
2,284.37
2,184.80
2,832.03
2,248.50
1,565.69
1,871.58
1,859.36
2,044.23
1,289.30
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-848.25
-593.23
-722.04
-450.27
-507.69
-392.26
-308.27
-461.69
-331.47
-264.20
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
104.04
-1,668.68
-854.01
-1,310.21
-4,522.63
-941.15
-1,249.86
-2,062.89
-965.10
-908.39
Net Fixed Assets
-489.16
-173.16
-509.84
-889.04
1,487.25
-534.38
-437.26
-692.52
-460.09
-601.86
Net Investments
-1,439.15
-1,239.74
-351.09
-30.10
164.99
-833.97
-985.31
-1,566.67
-464.50
-305.55
Others
2,032.35
-255.78
6.92
-391.07
-6,174.87
427.20
172.71
196.30
-40.51
-0.98
Cash from Financing Activity
-2,948.82
-348.72
-385.48
-1,325.68
3,104.06
164.78
-265.63
717.77
-753.17
-82.80
Net Cash Inflow / Outflow
223.67
-326.26
223.27
-254.13
322.24
397.06
47.82
52.55
-5.51
33.91
Opening Cash & Equivalents
508.36
853.47
610.35
858.15
545.84
175.76
143.01
90.46
95.97
62.06
Closing Cash & Equivalent
742.38
508.36
853.46
610.35
858.15
564.26
175.76
143.01
90.46
95.97

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
194.85
185.62
175.92
155.15
142.23
133.38
124.79
112.21
95.03
82.91
ROA
6.56%
6.50%
6.52%
4.97%
7.28%
7.85%
10.49%
13.97%
12.05%
10.94%
ROE
10.09%
10.37%
10.65%
8.72%
12.61%
12.10%
14.89%
18.64%
15.98%
15.40%
ROCE
12.53%
11.94%
10.20%
8.28%
13.24%
15.33%
19.05%
24.15%
19.96%
18.08%
Fixed Asset Turnover
1.88
1.79
1.25
1.36
1.40
1.26
1.47
1.69
1.61
1.79
Receivable days
54.10
55.36
68.17
61.60
57.62
57.94
58.66
70.11
77.94
87.29
Inventory Days
56.12
61.13
90.71
91.41
100.43
106.36
93.68
92.19
96.16
97.61
Payable days
57.55
59.02
57.37
46.96
51.51
52.17
44.93
48.58
50.51
56.11
Cash Conversion Cycle
52.66
57.47
101.50
106.05
106.55
112.14
107.41
113.72
123.59
128.78
Total Debt/Equity
0.18
0.29
0.29
0.33
0.46
0.16
0.12
0.11
0.00
0.09
Interest Cover
12.04
13.34
15.61
8.67
9.36
10.83
13.90
62.79
38.76
47.31

News Update:


  • Cipla’s step-down associate company receives complete response letter from USFDA for IV Tramadol
    15th Jun 2021, 09:32 AM

    Avenue disagrees with the FDA's interpretation of the data in the NDA and intends to continue to pursue regulatory approval for IV tramadol

    Read More
  • Cipla launches RT-PCR test kit ‘ViraGen’ for COVID-19 in India
    20th May 2021, 09:07 AM

    ViraGen is the company’s third offering in the Covid-19 testing segment

    Read More
  • Cipla reports 68% rise in Q4 consolidated net profit
    15th May 2021, 09:20 AM

    The company has reported a standalone net profit of Rs 413.41 crore for the quarter ended March 31, 2021

    Read More
  • Cipla signs licensing agreement with Eli Lilly
    10th May 2021, 10:47 AM

    This collaboration is a step further in Cipla’s efforts to enhance access to critical treatments for patients affected by the pandemic

    Read More
  • Cipla’s associate company incorporates wholly-owned subsidiary
    4th May 2021, 09:25 AM

    Iconphygital will be involved in the business of providing man-power staffing services

    Read More
  • Cipla enters into licensing agreement with MSD
    28th Apr 2021, 15:43 PM

    Cipla will be permitted to manufacture, market and distribute Molnupiravir in India and more than 100 low and middle income countries

    Read More
  • Cipla doubles Remdesivir production to meet 'unprecedented' demand
    13th Apr 2021, 16:34 PM

    The company has doubled production of COVID-19 medication remdesivir as the country battles a massive second wave of infections

    Read More
  • Cipla enters into agreement to become partner in ABCD Technologies LLP
    31st Mar 2021, 13:37 PM

    The target entity is a recently incorporated limited liability partnership

    Read More
  • Cipla’s affiliate enters into strategic partnership with SIGA Technologies
    23rd Mar 2021, 09:15 AM

    The partnership aims to deliver sustained innovation and access to novel antibacterial drugs, particularly against biothreats

    Read More
  • Cipla pledges support to ‘Terra Carta’ for sustainable future
    19th Mar 2021, 09:39 AM

    Since its launch in January 2021, the initiative has received support from 223 private sector organisations and 21 professional associations

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.